These highly regarded industry experts will help us accelerate our commercialization efforts and go-to-market strategies at ExcitePCR.
Pleasanton, Calif. (PRWEB) September 26, 2017
ExcitePCR today announced it has formed a Board of Advisors, with Dr. R. Paul Schaudies, Charles Pick and Anilrudh Venugopal, MD accepting advisory roles with the company.
Industry expertise for these advisors stretches from agricultural genomics to biodefense and from molecular diagnostics to infectious diseases.
“These highly regarded industry experts will help us accelerate our commercialization efforts and go-to-market strategies at ExcitePCR,” said Lyle L. Probst, CEO, President and Founder of ExcitePCR. “I believe their relevant experience, insights and relationships enhance our ability to execute our FireflyDX™ plans as we look to help save lives and lower costs in the healthcare, first responder, agricultural and food industries.”
About Paul Schaudies, Ph.D.
R. Paul Schaudies, Ph.D. is an internationally recognized expert in biodefense, biotechnology and nanotechnology, and he is the CEO and Co-founder of GenArraytion, a molecular diagnostics company. Dr. Schaudies was the science advisor to the U.S. Environmental Protection Agency (EPA) On-Scene Coordinator, as well as the Incident Commander of the 2001 anthrax incident in Washington, D.C. As a U.S. Army Officer, he supported the United Nations as an UNSCOM inspector in Iraq. Dr. Schaudies was also an AVP and Division Manager for Biological and Chemical Defense at Science Applications International Corporation (SAIC) for nine years, and he spent 13 years as an active duty U.S. Army officer before he retired as a Lieutenant Colonel. In addition, Dr. Schaudies was the Program Manager for Biological and Chemical Defense Research in the Central MASINT Office at the U.S. Defense Intelligence Agency (DIA), and he served as a Senior Researcher at the Walter Reed Army Institute of Research where he authored over 25 peer-reviewed scientific publications.
About Charles Pick
Charles Pick has over 25 years of experience in the agriculture and biotechnology industries and is the President of seqID, a firm that specializes in agricultural genomic technologies. Pick received a bachelor’s degree in Immunology at the University of Toronto and an MBA degree from the Smith School of Business at Queens University in Kingston, Ontario. He began his career in the seed industry becoming VP of Canadian turf operations at the Pickseed Companies Group before serving as head of business development for BASF’s agricultural genomics division (DNA LandMarks) for 11 years. Pick launched seqID in 2014 with the aim of bringing the latest genomic technologies and services to the agricultural sector.
About Anilrudh Venugopal, MD
Anilrudh Venugopal, MD is a board-certified Infectious Diseases and Internal Medicine physician with over 15 years of clinical experience. He previously held academic faculty appointments at the Wayne State School of Medicine and the Loyola University Chicago Stritch School of Medicine. Dr. Venugopal has a strong research background and has authored numerous publications and presentations on MRSA (Methicillin-resistant Staphylococcus aureus) and Clostridium difficile (C. diff.) infections. He also consults with pharmaceutical and medical device companies to assess the potential impact of their products and helps develop strategy to target and bring products to market.
Last month ExcitePCR announced its FireflyDX family of portable pathogen detection systems, led by its FireflyDX-Portable™, a rechargeable bookbag-sized realtime pathogen detection system the company says will be commercially available in summer 2018. Key among the benefits of the FireflyDX-Portable is its ability to provide highly accurate, PCR-based pathogen identification in 30 minutes or less anywhere on the planet at the Point-of-Care/Point-of-Need (POC/PON), including sample preparation time.
Headquartered in Pleasanton, California, ExcitePCR Corporation is developing portable pathogen detection systems based upon superior sample preparation and realtime PCR (Polymerase Chain Reaction) methodologies. Its FireflyDX technologies will deliver rapid automated Point-of-Care/Point-of-Care (POC/PON) sample preparation and highly accurate biohazard identification in a fraction of the time currently possible using existing PCR-based solutions.
ExcitePCR, FireflyDX and FireflyDX-Portable are each trademarks of ExcitePCR Corporation. All other trademarks are the property of their respective owners.
CONTACT: David Politis, dpolitis(at)excitepcr(dot)com, C: 801-556-8184